226950.KQ KOE
OliX Pharmaceuticals,Inc
1W: +13.7%
1M: +10.7%
3M: -30.1%
YTD: -9.5%
1Y: +124.2%
3Y: +687.1%
₩116,800.00 ($86.98)
-100.00 (-0.09%)
Weekly Expected Move ±12.2%
₩88232
₩102516
₩116800
₩131084
₩145368
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$14.7B
+158.3% ▲
5Y CAGR: +42.8%
Gross Profit
$0
-100.0% ▼
Operating Income
-$30.0B
+3.1% ▲
Net Income
-$16.2B
+60.1% ▲
EPS (Diluted)
$-804.00
+66.5% ▲
EBITDA
-$27.5B
+2.7% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $3.7B | $9.3B | $17.1B | $5.7B | $14.7B |
| YoY Growth | +48.5% | +153.7% | +83.1% | -66.7% | +158.3% |
| Cost of Revenue | $8.4B | $2.0B | $2.6B | $2.6B | $0 |
| Gross Profit | -$4.7B | $7.3B | $14.4B | $3.1B | $0 |
| Gross Margin | -127.4% | 78.8% | 84.5% | 53.7% | 0.0% |
| R&D Expenses | $15.0B | $17.4B | $18.5B | $19.5B | $0 |
| SG&A Expenses | $2.9B | $2.9B | $3.7B | $3.5B | $0 |
| Operating Expenses | $26.5B | $29.7B | $32.7B | $34.0B | $45.1B |
| Operating Income | -$24.2B | -$22.4B | -$18.2B | -$30.9B | -$30.0B |
| Operating Margin | -659.4% | -240.1% | -106.6% | -544.6% | -204.4% |
| Interest Expense | $2.4B | $2.9B | $3.5B | $4.7B | $1.8B |
| Income Before Tax | -$30.0B | -$29.1B | -$18.2B | -$41.1B | -$13.3B |
| Tax Expense | -$822M | -$995M | $932M | -$412M | $2.5B |
| Net Income | -$29.7B | -$19.5B | -$19.1B | -$40.7B | -$16.2B |
| Net Margin | -808.7% | -209.2% | -111.9% | -716.2% | -110.7% |
| EPS (Diluted) | $-2171.18 | $-1422.69 | $-1323.81 | $-2403.17 | $-804.00 |
| EBITDA | -$26.0B | -$24.2B | -$15.5B | -$28.3B | -$27.5B |
| Shares Outstanding | 14M | 14M | 14M | 17M | 20M |